Compare GSL & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSL | KLRA |
|---|---|---|
| Founded | 2007 | 2024 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2008 | 2026 |
| Metric | GSL | KLRA |
|---|---|---|
| Price | $41.89 | $12.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $51.00 | $42.40 |
| AVG Volume (30 Days) | 294.2K | ★ 1.3M |
| Earning Date | 11-09-2026 | 11-23-2026 |
| Dividend Yield | ★ 6.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.53 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.76 | $9.76 |
| 52 Week High | $46.57 | $23.82 |
| Indicator | GSL | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 52.61 |
| Support Level | $35.73 | $9.76 |
| Resistance Level | $41.95 | $19.15 |
| Average True Range (ATR) | 1.17 | 0.86 |
| MACD | -0.32 | 0.44 |
| Stochastic Oscillator | 27.03 | 82.09 |
Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.